Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy

The New England Journal of Medicine
Halle C F MoorePOEMS/S0230 Investigators

Abstract

Ovarian failure is a common toxic effect of chemotherapy. Studies of the use of gonadotropin-releasing hormone (GnRH) agonists to protect ovarian function have shown mixed results and lack data on pregnancy outcomes. We randomly assigned 257 premenopausal women with operable hormone-receptor-negative breast cancer to receive standard chemotherapy with the GnRH agonist goserelin (goserelin group) or standard chemotherapy without goserelin (chemotherapy-alone group). The primary study end point was the rate of ovarian failure at 2 years, with ovarian failure defined as the absence of menses in the preceding 6 months and levels of follicle-stimulating hormone (FSH) in the postmenopausal range. Rates were compared with the use of conditional logistic regression. Secondary end points included pregnancy outcomes and disease-free and overall survival. At baseline, 218 patients were eligible and could be evaluated. Among 135 with complete primary end-point data, the ovarian failure rate was 8% in the goserelin group and 22% in the chemotherapy-alone group (odds ratio, 0.30; 95% confidence interval [CI], 0.09 to 0.97; two-sided P=0.04). Owing to missing primary end-point data, sensitivity analyses were performed, and the results were co...Continue Reading

References

Aug 26, 1998·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·O PaganiH J Senn
Mar 31, 2000·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·P PoikonenC Blomqvist
May 3, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stephanie J LeeUNKNOWN American Society of Clinical Oncology
Jun 4, 2010·The New England Journal of Medicine·Sandra M SwainNorman Wolmark
Feb 1, 2011·Breast Cancer Research and Treatment·Antje SchubertCarsten Gründker
May 4, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bernd GerberUNKNOWN German Breast Group Investigators
Jan 11, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Pamela N MunsterSusan E Minton
Dec 25, 2012·Obstetrics and Gynecology·Eman A ElgindyAhmed M Abou-Setta
May 28, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·N H TurnerL Biganzoli
Feb 26, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kathryn J RuddyAnn H Partridge
Jun 3, 2014·The New England Journal of Medicine·Olivia PaganiUNKNOWN International Breast Cancer Study Group
Dec 17, 2014·The New England Journal of Medicine·Prudence A FrancisUNKNOWN International Breast Cancer Study Group

❮ Previous
Next ❯

Citations

Nov 7, 2015·Annals of Medicine·Charlotta Dabrosin
Mar 29, 2016·The Breast : Official Journal of the European Society of Mastology·Shani Paluch-ShimonFatima Cardoso
Jan 6, 2016·BMC Medicine·Matteo LambertiniPaola Anserini
Dec 31, 2015·Human Reproduction Update·Roberto MaggiPatrizia Limonta
Apr 4, 2016·European Journal of Obstetrics, Gynecology, and Reproductive Biology·Michael von WolffDominik Denschlag
Jan 27, 2016·Journal of Adolescent and Young Adult Oncology·Jessica E CampbellJennifer F Knudtson
Aug 25, 2015·The Breast : Official Journal of the European Society of Mastology·Jessica J TaoAntonio C Wolff
Sep 8, 2015·Fertility and Sterility·Jacques DonnezAntonio Pellicer
May 24, 2016·The Breast : Official Journal of the European Society of Mastology·Amirrtha SrikanthanEllen Warner
Mar 30, 2016·Journal de gynécologie, obstétrique et biologie de la reproduction·J BénardM Grynberg
Oct 16, 2015·Human Reproduction·Tommaso Falcone, Halle C F Moore
Sep 12, 2015·Future Oncology·Charlotte SonigoMichael Grynberg
May 18, 2016·Critical Reviews in Oncology/hematology·Mahmoud SalamaPeter Mallmann
Sep 1, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E SenkusUNKNOWN ESMO Guidelines Committee
Aug 27, 2015·Journal of the National Cancer Institute·Natalia C LlarenaJacqueline S Jeruss
Apr 1, 2015·Expert Opinion on Pharmacotherapy·Zeev Blumenfeld, Ayelet Evron
May 6, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A S CoatesUNKNOWN Panel Members
Jun 16, 2015·Journal of Women's Health·Kate E WaimeyMary Ellen Pavone
Jun 4, 2015·The New England Journal of Medicine·Halle C F MooreKathy S Albain
Mar 25, 2015·Nature Reviews. Clinical Oncology·Lisa Hutchinson
Jan 27, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·Zeev Blumenfeld
Jun 3, 2016·Future Oncology·Zeev Blumenfeld
Jun 23, 2016·Future Oncology·Miyuki Harada, Yutaka Osuga
Jun 21, 2016·Expert Opinion on Pharmacotherapy·Matteo LambertiniLucia Del Mastro
Dec 19, 2015·Fertility and Sterility·Hadassa RonessDror Meirow
Jan 17, 2016·European Journal of Haematology·Masa LasicaAndrew Grigg
Aug 11, 2015·The Breast : Official Journal of the European Society of Mastology·Shoshana M Rosenberg, Ann H Partridge
Sep 20, 2016·Climacteric : the Journal of the International Menopause Society·M F Garrido-Oyarzún, C Castelo-Branco
Oct 1, 2016·Cell Death and Differentiation·Valerio RossiFrancesca G Klinger
Nov 15, 2016·Journal of Adolescent and Young Adult Oncology·Andrea Bradford, Terri L Woodard
Jun 24, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Pamela N Munster
May 25, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kutluk Oktay, Giuliano Bedoschi
Feb 1, 2017·Proceedings of the National Academy of Sciences of the United States of America·Motohiro KanoDavid Pépin
Mar 9, 2017·Proceedings of the National Academy of Sciences of the United States of America·Kara N GoldmanRobert J Schneider
Apr 13, 2017·Expert Opinion on Pharmacotherapy·Matteo LambertiniLucia Del Mastro
Apr 12, 2017·Expert Review of Anticancer Therapy·Alicia TosoniAlba A Brandes

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.